Abstract
A series of aryltropane-based bivalent ligands was prepared and investigated for binding potency and for their ability to inhibit reuptake of human dopamine, serotonin and norepinephrine transporters. The bivalent ligand 4, comprised of linking an aryltropane by an octamethylene spacer showed high efficacy for the human dopamine transporter and had a discrimination ratio of 130.
MeSH terms
-
Adrenergic Uptake Inhibitors / chemical synthesis
-
Adrenergic Uptake Inhibitors / pharmacology
-
Chromatography, Thin Layer
-
Dopamine Plasma Membrane Transport Proteins
-
Dopamine Uptake Inhibitors / chemical synthesis
-
Dopamine Uptake Inhibitors / pharmacology
-
Humans
-
Ligands
-
Magnetic Resonance Spectroscopy
-
Mass Spectrometry
-
Membrane Glycoproteins*
-
Membrane Transport Proteins / metabolism
-
Nerve Tissue Proteins*
-
Neurotransmitter Uptake Inhibitors / chemical synthesis*
-
Neurotransmitter Uptake Inhibitors / pharmacology*
-
Norepinephrine / metabolism
-
Selective Serotonin Reuptake Inhibitors / chemical synthesis
-
Selective Serotonin Reuptake Inhibitors / pharmacology
-
Tropanes / chemical synthesis*
-
Tropanes / pharmacology*
Substances
-
Adrenergic Uptake Inhibitors
-
Dopamine Plasma Membrane Transport Proteins
-
Dopamine Uptake Inhibitors
-
Ligands
-
Membrane Glycoproteins
-
Membrane Transport Proteins
-
Nerve Tissue Proteins
-
Neurotransmitter Uptake Inhibitors
-
Serotonin Uptake Inhibitors
-
Tropanes
-
Norepinephrine